Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 20/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30209260 | 1.00 | GLP1R (0.58) | GLP1R | |
| SCHEMBL24147544 | 1.00 | GLP1R (0.58) | GLP1R | |
| SCHEMBL24400979 | 0.93 | GLP1R (0.52) | GLP1R | |
| SCHEMBL24400741 | 0.93 | GLP1R (0.52) | GLP1R | |
| SCHEMBL25925526 | 0.92 | GLP1R (0.55) | GLP1R | |
| SCHEMBL30209317 | 0.92 | GLP1R (0.52) | GLP1R | |
| SCHEMBL25119864 | 0.92 | GLP1R (0.52) | GLP1R | |
| SCHEMBL24400945 | 0.92 | GLP1R (0.52) | GLP1R | |
| SCHEMBL24400905 | 0.92 | GLP1R (0.52) | GLP1R | |
| SCHEMBL24400981 | 0.91 | GLP1R (0.53) | GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203057-A1 | FIVE-MEMBERED HETEROAROMATIC IMIDAZOLE COMPOUND AND USE THEREOF | HANGZHOU SCIWIND BIOSCIENCES CO., LTD (CN) | 2023-06-29 | — | — | US | disclosed |
| EP-4155313-A1 | FIVE-MEMBERED HETEROAROMATIC IMIDAZOLE COMPOUND AND USE THEREOF | Hangzhou Sciwind Biosciences Co., Ltd. (CN) | 2023-03-29 | — | — | EP | disclosed |
| US-11542272-B2 | Five-membered heteroaryl-fused imidazole compound and application thereof | HANGZHOU SCIWIND BIOSCIENCES CO., LTD (CN) | 2023-01-03 | — | — | US | disclosed |
| US-20220135588-A1 | Five-Membered Heteroaryl-Fused Imidazole Compound And Application Thereof | HANGZHOU SCIWIND BIOSCIENCES CO., LTD (CN) | 2022-05-05 | — | — | US | disclosed |
| CN-113831337-A | GLP-1 receptor agonist, and pharmaceutical composition and use thereof | 广州市恒诺康医药科技有限公司 | 2021-12-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135588-A1 | Five-Membered Heteroaryl-Fused Imidazole Compound And Application Thereof | GLP1R, GIPR, GPR119 | GLP1R 1/4885 |
| US-20230203057-A1 | FIVE-MEMBERED HETEROAROMATIC IMIDAZOLE COMPOUND AND USE THEREOF | GLP1R, GIPR, GPR119 | GLP1R 1/4885 |
| US-11542272-B2 | Five-membered heteroaryl-fused imidazole compound and application thereof | GLP1R, GIPR, GPR119 | GLP1R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.